<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05121350</url>
  </required_header>
  <id_info>
    <org_study_id>ALTN-â…¢-04</org_study_id>
    <nct_id>NCT05121350</nct_id>
  </id_info>
  <brief_title>A Clinical Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Parallel-controlled Phase III Trial to Evaluate the Efficacy and Safety of Anotinib Hydrochloride Capsule Combined With Epirubicin Hydrochloride Versus Placebo Combined With Epirubicin Hydrochloride in First-line Treatment of Advanced Soft Tissue Sarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chia Tai Tianqing Pharmaceutical Group Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multicenter, randomized, double-blind, parallel-controlled Phase III trial to evaluate the&#xD;
      efficacy and safety of anotinib hydrochloride capsule combined with epirubicin hydrochloride&#xD;
      versus placebo combined with epirubicin hydrochloride in first-line treatment of advanced&#xD;
      soft tissue sarcoma&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS) assessed by independent review committees (IRC)</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Time from the first dose to the first documentation of progression disease (PD) or death from any cause, whichever occurs first</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>Baseline up to die</time_frame>
    <description>From randomization to the time of death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression free survival (PFS) assessed by investigator</measure>
    <time_frame>Baseline up to 12 months</time_frame>
    <description>Time from the first dose to the first documentation of PD or death from any cause, whichever occurs first</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>The sum of percentage of participants with complete response rate and partial response rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease control rate (DCR)</measure>
    <time_frame>Baseline up to 25 months</time_frame>
    <description>percentage of participants with complete response, partial response plus stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of overall response (DOR)</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>the time from the date of first documentation of a CR or PR to the date of first documentation of tumor progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degradation rate</measure>
    <time_frame>Baseline up to 6 months</time_frame>
    <description>Proportion of patients with tumor regression meeting surgical resection criteria in each group during the study period</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">256</enrollment>
  <condition>Soft Tissue Sarcoma</condition>
  <arm_group>
    <arm_group_label>Arotinib hydrochloride capsule + Epirubicin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Arotinib hydrochloride capsule combined with epirubicin, 21 days as a treatment cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + Epirubicin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Placebo combined with epirubicin, 21 days as a treatment cycle</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Anlotinib hydrochloride capsule</intervention_name>
    <description>Anlotinib hydrochloride is a multi-target tyrosine kinase inhibitor.</description>
    <arm_group_label>Arotinib hydrochloride capsule + Epirubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>Epirubicin can inhibit the synthesis of DNA and RNA.</description>
    <arm_group_label>Arotinib hydrochloride capsule + Epirubicin</arm_group_label>
    <arm_group_label>Placebo + Epirubicin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Arotinib hydrochloride capsule placebo</intervention_name>
    <description>Placebo of Anlotinib hydrochloride capsule</description>
    <arm_group_label>Placebo + Epirubicin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 1.&#xD;
&#xD;
          -  Life expectancy &gt;=3 months.&#xD;
&#xD;
          -  Female patients of childbearing age should agree to use contraceptive measures during&#xD;
             the study period and for at least 6 months after study is stopped; male patients&#xD;
             should agree to use contraception during the study period and for at least 6 months&#xD;
             after study is stopped.&#xD;
&#xD;
          -  Understood and signed an informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosed and/or treated additional malignancy within 5 years before the first dose.&#xD;
&#xD;
          -  With factors affecting oral medication.&#xD;
&#xD;
          -  Received major surgical treatment, open biopsy or obvious traumatic injury within 4&#xD;
             weeks before the first dose.&#xD;
&#xD;
          -  A history of psychotropic drug abuse or have a mental disorder.&#xD;
&#xD;
          -  Any severe and/or uncontrolled diseas.&#xD;
&#xD;
          -  Has received Chinese patent medicines with anti-tumor indications within 2 weeks&#xD;
             before the first dose.&#xD;
&#xD;
          -  Has participated in other clinical studies within 4 weeks before the first dose.&#xD;
&#xD;
          -  According to the judgement of the investigators, there are other factors that subjects&#xD;
             are not suitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shanghai Niu, Bachelor</last_name>
    <phone>13801132522</phone>
    <email>moonlight003@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YUHONG ZHOU, Doctor</last_name>
    <phone>13918286810</phone>
    <email>Zhou.yuhong@zs-hospital.sh.cn</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Beijing Jishuitan Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiaohui Niu, Bachelor</last_name>
      <phone>13801132522</phone>
      <email>moonlight003@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Wei Guo, Doctor</last_name>
      <phone>13701195504</phone>
      <email>bonetumor@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fudan University Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>YUHONG ZHOU, Doctor</last_name>
      <phone>13918286810</phone>
      <email>Zhou.yuhong@zs-hospital.sh.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>November 15, 2021</study_first_submitted>
  <study_first_submitted_qc>November 15, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 16, 2021</study_first_posted>
  <last_update_submitted>November 15, 2021</last_update_submitted>
  <last_update_submitted_qc>November 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epirubicin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

